Ocugen, Inc. Common Stock
Here’s whether Ocugen, Inc. Common Stock (OCGN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); RSI 58 — healthy momentum range; strong 1-year return of +31.1%. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-0.64% over 10 days). Currently 50.5% off its 52-week high. Score: +0/7.
OCGN is trading below its 200-day MA ($1.51) — a key warning sign the longer-term trend is under pressure. An RSI of 58.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +31.1% compares to +20.4% for SPY (beat the market by 10.7%). The current 50.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.